Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at risk populations

Gwenda Simons, Joshua Caplan, Rachael DiSantostefano, Jorien Veldwijk, Matthias Englbrecht, Schölin Bywall Karin, Ulrik Kihlbom, Karim Raza, Marie Falahee

Research output: Contribution to journalReview articlepeer-review

17 Downloads (Pure)


Treatments used for rheumatoid arthritis (RA) are under investigation for their efficacy to prevent RA in at risk groups. It is therefore important to understand treatment preferences of those at risk. We systematically reviewed quantitative preference studies of drugs to treat, or prevent RA, to inform the design of further studies and trials of RA prevention. Stated preference studies for RA treatment or prevention were identified through a search of five databases. Study characteristics and results were extracted and the relative importance of different types of treatment attributes was compared across populations. Twenty studies were included: 1720 of RA treatments (1518 of patients; 2 of the general public), and 3 prevention studies with first-degree relatives (FDRs). Benefits, risks, administration method and cost (when included) were important determinants of treatment choice. A benefit was more important than a risk attribute in 8/15half of the studies of RA treatment that included a benefit attribute, and 2/3 studies of RA prevention. There was variability in the relative importance of attributes across the few prevention studies. In studies with non-patient participants, attributes describing confidence in treatment effectiveness/safety were more important determinants of choice than in studies with patients. Most preference studies relating to RA are of treatments for established RA. Few studies examine preferences for treatments to prevent RA. Given intense research focus on RA prevention, additional preference studies in this context are needed. Variation in treatment preferences across different populations is not well understood and direct comparisons are needed.
Original languageEnglish
Article number55
Number of pages12
JournalArthritis Research & Therapy
Publication statusPublished - 22 Feb 2022

Bibliographical note

Funding Information:
KR reports grants from Abbvie and Pfizer, and personal fees from Abbvie, Pfizer, Sanofi, Lilly, Bristol Myers Squibb, UCB, Janssen, and Roche Chugai outside the submitted work. RLD is employed by Janssen Research & Development and is a shareholder of Johnson & Johnson.

Funding Information:
The current systematic review was conducted as part of a clinical case study for the Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project. PREFER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). K. Raza is supported by the NIHR Birmingham Biomedical Research Centre.

Publisher Copyright:
© 2022, The Author(s).


  • Attributes
  • Preventive treatment
  • Rheumatoid arthritis
  • Systematic review
  • Treatment preferences

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at risk populations'. Together they form a unique fingerprint.

Cite this